Frank Volovovitz (born 1948)

Wikipedia 🌐 NONE

ASSOCIATIONS


https://www.ancestry.com/discoveryui-content/view/44879916:1788?tid=&pid=&queryId=a312ccffc36fb8a64022f394498510d1&_phsrc=llt685&_phstart=successSource

  • Name : Franklin Volvovitz

  • Birth Date : 9 Sep 1948

  • Residence Date : 1995

  • Address : 12 Indian Trail Rd / Woodbridge, CT / 06525

  • Second Residence Date : 1995

  • Second Address : PO Box 9666 / New Haven, CT / 06536-0666


Frank Volvovitz

President at Biomedisyn Corporation

Woodbridge, Connecticut, United States


https://www.linkedin.com/in/frank-volvovitz-6328b585/

2021-09-09-linkedin-com-frank-volovovitz.pdf

https://drive.google.com/file/d/1ls7RrzUQsOXgVP1xjjRiym6Qjy5i8AQD/view?usp=sharing

2021-09-09-linkedin-com-frank-volovovitz-img-1.jpg

https://drive.google.com/file/d/1dfs_HAKaD_nHatSyK9lD78_hSQ1PpZoT/view?usp=sharing


Experience

  • President

  • Company Name

  • Biomedisyn Corporation

  • Dates Employed

  • Dec 1994 – Present

  • Employment Duration

  • 26 yrs 10 mos

  • Location

  • Woodbridge, Connecticut

  • Frank founded Biomedisyn and has served as its President since inception. Biomedisyn is developing small molecule, multifunctional drugs to improve the lives of people with neurodegenerative diseases. The Company’s product pipeline has been supported by grants from the National Institutes of Health (NIH) and the United States Army.


  • There is growing recognition that effective treatment of neurodegenerative diseases may require drugs or drug combinations that simultaneously target multiple mechanisms. Available drugs mainly target a single mechanism and do not effectively slow disease progression. Biomedisyn’s drug candidates target multiple events in a disease pathway attenuating mechanisms common to many neurological disorders that underlie disease progression and clinical deterioration.

  • see less


  • President, CEO, Founder

  • Company Name

  • Protein Sciences Corporation

  • Dates Employed

  • May 1983 – Dec 1994

  • Employment Duration

  • 11 yrs 8 mos

  • Location

  • Meriden, Connecticut

  • Frank founded and served as the President and Chief Executive Officer (May 1983 until December 1994) of Protein Sciences Corp. (formerly MicroGeneSys, Inc.) a biotechnology company engaged in the development of new vaccines. In January 2013, the recombinant influenza vaccine pioneered by his team received FDA approval under the trade name of Flublok. Additionally, under Frank's leadership, new vaccines for malaria, HIV/AIDS and colon cancer were brought from concept to human clinical trials. Their development required first the creation of a new vaccine manufacturing platform based on the use of a recombinant insect virus and insect cells, which his team pioneered in connection with developing the first HIV/AIDS vaccine to enter U.S. clinical trials. He established a strategic collaboration with American Home Products (now Pfizer) that provided a multimillion equity investment and supported further development of the HIV/AIDS vaccine. He arranged multiple rounds of private financing and a multimillion dollar loan for Protein Sciences with the State of Connecticut and City of Meriden.